EnvestnetNYSE: ENV

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ENV's top line in the third quarter of 2024 benefits from improved segmental performance.

Envestnet (ENV) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.56 per share a year ago.

New Options Strategy Quantitative Portfolio (QP) is the Latest Solution to Emerge from Envestnet Affiliate QRG's Systematic Approach to Investment Management Advisors can Offer a Personalized Solution for Mitigating the Risk of a Concentrated Stock Holding, While Offsetting Capital Gains, Over Multiple Years BERWYN, Pa. , Oct. 28, 2024 /PRNewswire/ -- Envestnet, a leading provider of integrated technology, data intelligence and wealth solutions—and also one of the largest direct index separately managed account providers—has launched an Options Strategy Quantitative Portfolio (QP) to address the market volatility, tax risk, and liquidity risk associated with concentrated stock positions, and to help advisors and their clients unwind these positions.

Consistent growth in recurring revenues, and improving efficiency and competitiveness are benefiting Envestnet's performance.

Kasowitz Benson Torres Is Acting As Lead Counsel For FinancialApps NEW YORK , Sept. 27, 2024 /PRNewswire/ -- Financial technology pioneer FinancialApps's $100 million lawsuit for trade secret misappropriation, tortious interference, and unfair competition against wealth management company Envestnet ($ENV) – whose acquisition by Bain Capital in a $4.5 billion deal was approved by shareholders earlier this week – is now headed to a jury trial in Delaware Federal Court.

BERWYN, Pa. , Sept. 24, 2024 /PRNewswire/ -- Envestnet, Inc. (NYSE: ENV) ("Envestnet," or the "Company"), a leading provider of integrated technology, data intelligence, and wealth solutions, today announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the pending acquisition of the Company by affiliates of vehicles managed or advised by Bain Capital (the "Merger").

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma's cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105.